📊 OKUR Key Takeaways
Is OnKure Therapeutics, Inc. (OKUR) a Good Investment?
OnKure is a clinical-stage pharmaceutical company with severe operational losses ($15.2M net loss on only $458K revenue) and no clear path to profitability. While the strong balance sheet ($192.1M cash, zero debt) provides substantial runway, the fundamental lack of revenue generation and massive cash burn (-$12.9M annually) represent significant headwinds that overshadow balance sheet strength.
OnKure shows minimal revenue alongside extremely negative margins and substantial cash burn, consistent with a pre-commercial biotech profile. The debt-free balance sheet and strong liquidity are positives, but the current cash level covers roughly a year of operations at the present burn rate, implying a high likelihood of future financing or dilution absent meaningful, recurring revenue.
OnKure Therapeutics, Inc. Key Strengths (OKUR)
- Fortress balance sheet with $192.1M cash and zero debt, providing 14+ years of runway at current burn rate
- Exceptional liquidity position (13.78x current ratio) with minimal liabilities ($14.3M), ensuring operational flexibility
- Improving loss trajectory with net losses declining 13% YoY, suggesting operational efficiency gains or development progress
- Strong cash position and 10.28x current ratio
- Debt-free capital structure (0.00x D/E)
- Minimal capex needs, preserving operational flexibility
OKUR Stock Risks: OnKure Therapeutics, Inc. Investment Risks
- Pharmaceutical development risk: drug candidates may fail clinical trials, regulatory approval, or market adoption, leaving cash burn unreimbursed
- Minimal revenue ($458K) with operating margin of -3409% indicates company is far from commercialization and profitability
- Accelerating cash burn risk: as clinical programs advance (Phase 2/3 trials), monthly burn rate typically increases, potentially eroding runway faster than current projections
- Dilution risk from future capital raises or employee stock compensation given lack of profits to support share buybacks
- Severe operating and net losses with deeply negative margins
- Short cash runway (~12 months) implying dilution/financing risk
- Low and potentially non-recurring revenue, limited visibility
Key Metrics to Watch
- Monthly cash burn rate and runway extension/contraction
- Clinical trial progress and regulatory milestones (FDA meetings, trial enrollment, safety signals)
- Revenue growth trajectory and market adoption of any approved/commercialized products
- Operating expense trend relative to clinical development progress
- Equity dilution from financing activities or stock-based compensation
- Quarterly operating cash burn and remaining cash runway
- Recurring revenue growth and operating margin trend
OnKure Therapeutics, Inc. (OKUR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.78x current ratio provides a solid financial cushion.
OKUR Profit Margin, ROE & Profitability Analysis
OKUR vs Healthcare Sector: How OnKure Therapeutics, Inc. Compares
How OnKure Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OnKure Therapeutics, Inc. Stock Overvalued? OKUR Valuation Analysis 2026
Based on fundamental analysis, OnKure Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OnKure Therapeutics, Inc. Balance Sheet: OKUR Debt, Cash & Liquidity
OKUR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OnKure Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-15.28 indicates the company is currently unprofitable.
OKUR Revenue Growth, EPS Growth & YoY Performance
OnKure Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
OKUR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OnKure Therapeutics, Inc. (CIK: 0001637715)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 8, 2026 | 4 | xslF345X06/ownership.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_100623.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_100605.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_100613.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_100628.xml | View → |
❓ Frequently Asked Questions about OKUR
What is the AI rating for OKUR?
OnKure Therapeutics, Inc. (OKUR) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OKUR's key strengths?
Claude: Fortress balance sheet with $192.1M cash and zero debt, providing 14+ years of runway at current burn rate. Exceptional liquidity position (13.78x current ratio) with minimal liabilities ($14.3M), ensuring operational flexibility. ChatGPT: Strong cash position and 10.28x current ratio. Debt-free capital structure (0.00x D/E).
What are the risks of investing in OKUR?
Claude: Pharmaceutical development risk: drug candidates may fail clinical trials, regulatory approval, or market adoption, leaving cash burn unreimbursed. Minimal revenue ($458K) with operating margin of -3409% indicates company is far from commercialization and profitability. ChatGPT: Severe operating and net losses with deeply negative margins. Short cash runway (~12 months) implying dilution/financing risk.
What is OKUR's revenue and growth?
OnKure Therapeutics, Inc. reported revenue of $458.0K.
Does OKUR pay dividends?
OnKure Therapeutics, Inc. does not currently pay dividends.
Where can I find OKUR SEC filings?
Official SEC filings for OnKure Therapeutics, Inc. (CIK: 0001637715) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OKUR's EPS?
OnKure Therapeutics, Inc. has a diluted EPS of $-1.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OKUR's fundamental grade?
Based on our AI fundamental analysis in June 2026, OnKure Therapeutics, Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OKUR stock overvalued or undervalued?
Valuation metrics for OKUR: ROE of -8.2% (sector avg: 15%), net margin of -3,309.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OKUR's AI grade for 2026?
Our dual AI analysis gives OnKure Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OKUR's free cash flow?
OnKure Therapeutics, Inc.'s operating cash flow is $-12.9M, with capital expenditures of $5.0K. FCF margin is -2,826.0%.
How does OKUR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,309.4% (avg: 12%), ROE -8.2% (avg: 15%), current ratio 13.78 (avg: 2).